7:50 am
Lisa Egbuonu-Davis
Lisa Egbuonu-Davis, MD, MPH, MBA
Vice President, Global Patient Centered Outcomes and Solutions
Sanofi

8:00 am

Healthcare stakeholders are in the midst of radical change, with a growing shift from product-centricity to patient-centricity. Organizational structural changes backed by new strategies and benchmarks are being put in place to develop innovative patientfocused solutions that enhance health outcomes, reduce waste, and contribute to preventative health and disease management. Although the industry is aware that we must address patient needs in its entirety to have maximum impact, questions around the meaning of “patientcentricity” continue to exist. In order to create meaningful patient centric solutions, manufacturers must adopt a patient centric strategy across the product lifecycle, identify areas for culture and organizational change, and determine their role in adding value to the patient beyond the pill.

  • Understand how to develop patient focused solutions that align with commercial goals and improve the patient experience
  • Discuss ways to successfully transform internal culture from productcentered to patient-centered
  • Determine a patient-focused strategy across the product lifecycle, research and development and commercialization process
  • Co-create meaningful patient solutions to deliver value, enhance patient engagement, and improve health outcomes
Todd Hobbs
Todd Hobbs, MD
Chief Medical Officer
NovoNordisk

8:30 am

In an era of increasing interest around patient centricity, stakeholders are turning to partnerships to improve quality and patient outcomes. As changes in payer reimbursement, regulatory requirements, and stakeholder incentives continue to take shape, it is important to align value incentives to improve care coordination and drive a better patient experience.

  • Understand best practices for improving partnerships with key stakeholder groups
  • Establish trust and align value incentives to improve patient care coordination and improve the patient experience
  • Understand the role of each stakeholders in health care delivery and opportunities to collaborate in preventative health, disease management, and advocacy initiatives
  • Forge new partnerships to champion co-creation and shared decision-making efforts

Moderator:

Sara Laskey
Sara Laskey, MD
Vice President and Chief Experience Officer, Office of Patient Experience
The Metro Health System

Pharma Perspective:

Pablo Lapuerta
Pablo Lapuerta
Chief Medical Officer
Lexicon Pharmaceuticals

Health System Perspective:

Larry Kaiser
Larry Kaiser
CEO
Temple University Health System

9:15 am

Throughout the healthcare industry, pharmaceutical, biotech, patient groups and policy makers alike, are continuing the mission to enhance collaboration with each other while advancing innovation and patient care. At the very center of this phenomenon is patient advocacy, a role which is becoming increasingly vital to the success of pharmaceutical and biotech companies. From an influential force creating change in state and national legislation to a champion revolutionizing care and support for patients, the advocacy function is fundamental to embracing patient centric healthcare. It is essential advocacy executives stay abreast of public policy, remain current on trends within the industry and continue to make elemental advocacy advancements as organizations develop. Defining the role of advocacy in this multifaceted healthcare landscape is of critical importance to continued success for patients, patient groups, and pharmaceutical organization alike. Through an in-depth discussion, define the role of advocacy and steps that can be taken to achieve long-term success in advocacy goals.

  • Identify advocacy’s role in the value conversation around drug pricing, access and reimbursement, to ensure patients have access to quality healthcare
  • Examine advocacy’s role in state and federal legislation and define steps to ensure success in long term advocacy goals
  • Uncover top priorities of patient groups to evolve legislation and explore multiple ways to get involved and assist in advancing initiatives
  • Explore top engagement and education efforts to ensure patients, providers, and advocacy organizations are aware of new therapies and assistance programs
Moderator:
Mary Dunkle
Mary Dunkle
Vice President of Educational Initiatives
NORD

Panelists:
Jayne C. Gershkowitz
Jayne C. Gershkowitz
Chief Patient Advocate
Amicus Therapuetics

John Rother
John Rother
President and CEO
National Coalition on HealthCare

Mark Schoeberl
Mark Schoeberl
Executive Vice President Advocacy & Health Quality
American Heart Association

10:20 am

Enhancing the patient experience requires pharma to look at how patients navigate the health care ecosystem holistically. It is critical to embrace an approach of understanding, roadblocks and hurdles they face backed by financial and socio-economic barriers patients have to deal with. Unless manufacturers put themselves in the shoes of their patients, patient-centricity will continue to remain a concept the industry is striving for instead of a reality to embrace. Developing a patient centric strategy requires an in depth understanding of how pharma can support patients throughout their journey. This session will give you an insight into the real life struggles of a patient and aid you with looking at your processes through a different lens.

Moderator:

Jack Barrette
Jack Barrette
CEO
WEGO Health

Panelists:

Michael Curry
Michael Curry
Patient and Family Advisor
The MetroHealth System

Carol Kivler
Carol Kivler, MS, CSP
Mental Health Speaker and Author

Marla Jan Wexler
Marla Jan Wexler
Patient and Creator
Luck Fupus

11:00 am

A key theme across various stakeholders focuses on developing an integrated patient-centric strategy across the drug development, commercialization and post-commercialization process. In order to ensure the patient voice is incorporated at every stage of a product life cycle, pharma must break down the silos between clinical, advocacy, and patient solution functions to adopt an integrated patient-centric strategy. As part of this discussion you will hear from leaders in each of these functions as they shed light on ways to collaborate and achieve a cohesive strategy to achieve a common goal.

Moderator:

Luther Clark
Luther Clark, MD, FACC, FACP
Global Director, Scientific Medical and Patient Perspective
Merck

Panelists:

Patient Centered Clinical Trial Representative:
Victoria DiBiaso
Victoria DiBiaso
Vice President Global Head Clinical Operations Strategy and Collaboration
Sanofi

Patient Advocacy Representative:
Scott Williams
Scott Williams
Vice President Global Patient Advocacy and strategic partnerships
EMD Serono

Patient Adherence Representative:
Douglas Stover
Douglas Stover
Vice President Patient Experience
UCB

1:45 pm
Kristina Broadbelt
Kristina Broadbelt
Director, Patient Advocacy
Horizon Pharma

1:50 pm
Clinton Moore
Clinton Moore
President
Cystinosis Research Network

2:00 pm

Involving the patient voice in all aspects of drug development requires pharma to comply with FDA regulations. As the FDA continues to roll out patient representation and engagement initiatives, there is opportunity for manufacturers, advocacy groups, and government executives to collaborate on effective ways to engage patients. As part of this session hear first-hand from the FDA on their expectations as well as best practices on collaborating with them to incorporate patient insights into your business model.

  • Navigate the regulatory landscape to overcome hurdles to patient adherence and engagement
  • Gain clarity on FDA Guidelines to effectively engage patient groups in co-creating solutions
  • Discuss current FDA programs and future initiatives around policy efforts
  • Discover FDA initiatives to diversify clinical trials and improve the patient experience

Moderator:

Jodie Gillon
Jodie Gillon, MPH
Global Medical Lead, Patient Engagement Rare Diseases
Pfizer Innovative Health

Panelists:

Andrea Furia Helms
Andrea Furia Helms
Patient Representative Program
FDA

Pujita Vaidya
Pujita Vaidya, MPH
Director (Acting), Decision Support and Analysis Team (DSAT) Office of Program and Strategic Analysis (OPSA)/ Office of Strategic Programs (OSP)
FDA

2:55 pm

As health care reform continues to prioritize better management of health care costs, creating successful adherence programs can result in huge cost savings. Manufacturers are finding they are able to learn from Payers with successful MTM interventions, as well as collaborate with ACO’s and IDNs to improve medication therapy management. Explore various initiatives in both commercial and pre-commercial settings to develop strategies for patient support and adherence across the stakeholder landscape.

  • Align support programs with Payers, ACOs and IDNs to deliver patient-centered care and ensure optimal engagement and program scalability across specific patient populations
  • Learn what Payers deem to be a critical metrics to measure the effectiveness of an adherence program
  • Explore the various internal MTM interventions payers, ACOs and IDNs use to increase the quality of care and recognize cost savings
  • Discover opportunities for industry partnerships to collaborate on adherence programs
  • Explore opportunities to support patients across the continuum of care and in the pre-approval stage

Moderator:

Jonathan Fox
Jonathan Fox
Life Sciences Strategy
Deloitte Consulting LLP

Panelists:

Susan Hopkins
Susan Hopkins
Associate Director, Care Redesign and Adherence Lead
Merck

Pablo Lapuerta
Pablo Lapuerta
Chief Medical Officer
Lexicon Pharmaceuticals

Michael Stirratt
Michael Stirratt
Scientific Program Officer
National Institute of Health

4:00 pm

Patients who have a specialty drug often suffer from the most life threatening diseases. As specialty drugs typically come with a high cost and address diseases that are complex in nature, manufacturers must understand how to develop support strategies to help patients adhere to highly managed medications. Explore how to maintain adherence with chronic disease patients.

  • Discover the driving force behind pharma developing services beyond traditional patient support programs
  • Identify the key characteristics of best-in-class support programs - what works and what doesn’t?
  • Visualise the immense possibilities opened-up by technology and discuss how far pharma should venture
Brian Flatley
Business Strategy & Engagement Director
S3 Connected Health

Matt Norton
Matt Norton
Director of Strategy & Client Solutions
S3 Connected Health

4:30 pm

Developing and implementing interventions to improve health behaviors requires tailored patient interventions that overcome the barriers to treatment adherence and self-management. Stakeholders have the opportunity to design innovative patient support tools, services and programs to promote adherence. As part of this session you will gain first hand insight into key steps to employing an effective adherence program for measurable results and improved patient outcomes

  • Provide an overview of medication non-adherence and its impact on patients and the U.S. healthcare system
  • Expose common misperceptions regarding medication adherence and provide useful insights about patient medication decision making.
  • Develop an evidence-based, patient-centered resource designed to gauge the likelihood of patient non-adherence.
Susan Hopkins
Susan Hopkins
Associate Director, Care Redesign and Adherence Lead
Merck

5:00 pm

Designing an effective adherence program requires an understanding of how to leverage patient insights to understand the behavioral, social and economic factors that influence patient behavior. Collecting, collating and analyzing data through the right sources can provide insight into patients who follow their medication regiment and help predict profiles of patients who may not. This information allows stakeholders to intervene at an earlier stage and collaborate with organizations that are developing patient services and tools that fits into those patients’ self-management skills. Learn how best to leverage data to gain insights into specific populations, and measure patient adherence more effectively and accurately.

  • Understand how to better leverage data and glean informative insights to measure patient adherence
  • Discover how to use patient data to predict the risk of non-adherence
  • Learn how to apply adherence data to measure the effectiveness of a program
Lisa Egbuonu-Davis
Lisa Egbuonu-Davis, MD, MPH, MBA
Vice President, Global Patient Centered Outcomes and Solutions
Sanofi